Spin-offs

Some remarkable spin-offs backed by Inserm's technology. More than 120 start-ups companies have been created over the past 35 years.

 

puce grise2 DNA THERAPEUTICS cancer

dna therapeutics

puce grise2  EYEVENSYS ocular diseases

eyevensys ok

puce grise2  FOVEA PHARMACEUTICALS ocular diseases

fovea pharmaceuticals

puce grise2  GENFIT
Alternext: ALGFT;
ISIN: FR0004163111

cardiovascular

genfit

puce grise2  GENOWAY
Alternext-Euronext: AlGEN;
ISIN: FR0004053510

animal models

genoway

puce grise2  GRAFTYS bone tissue engineering

graftys

puce grise2  INNATE PHARMA

Euronext: FR0010331421 IPH

 

cancer and inflammatory diseases

innate pharma

puce grise2  INTEGRAGEN
Euronext;

Isin: FR0010908723

autism and oncology

integragen

puce grise2  HYBRIGENICS
ISIN: FR0004153930
Mnémo: ALHYG

cancer

hybrigenics

puce grise2  NOVAGALI PHARMA
ISIN code: FR0010915553
Ticker: NOVA

ocular diseases

novagali

puce grise2  SENSORION inner ear disorders sensorion
puce grise2  TCLAND EXPRESSION biomarkers for inflammatory chronic diseases

tcland

puce grise2  TRANSGENE
Euronext: FR0005175080

cancer and chronic infectious diseases

transgene

puce grise2  TROPHOS neurology and cardiology

trophos

puce grise2  TXCELL all therapy for chronic inflammatory diseases txcell

Increase font size Default font size Decrease font size